Today: 10 June 2026
Browse Category

NASDAQ:SCNX 16 October 2025 - 24 October 2025

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Shares Skyrocket 350% on FDA-Approved Drug Launch – What’s Next?

Scienture (NASDAQ: SCNX) soared 355% to close near $2.60 on Oct. 23, 2025, after announcing the launch of Arbli, the first FDA-approved liquid losartan. Shares fell about 25% after hours and swung between $0.83 and $2.60 on Oct. 24. The company secured distribution deals covering over 100 million patients and converted all convertible debt to equity earlier in October. Analyst coverage remains sparse, with a consensus “Sell” rating.
24 October 2025
·
Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (NASDAQ: SCNX) jumped up to 45% in pre-market trading on Oct. 23, 2025, after announcing its first commercial sales of Arbli, the only FDA-approved ready-to-use liquid losartan. Trading volume surged to 77 million shares, far above its 4 million average. Despite the spike, SCNX remains down over 90% for the year. The company recently eliminated all debt by converting debentures to equity.
23 October 2025
··
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX shares jumped over 30% in early trading Oct. 16 after Scienture announced Arbli, the first FDA-approved ready-to-use liquid losartan, is now available through major wholesalers. The stock hit an intraday high of $1.12 before trading near $0.71 by mid-day. Scienture recently secured a major rebate deal to drive Arbli’s adoption. Analysts remain cautious, citing weak financials and high volatility.
16 October 2025
··

Stock Market Today

  • JPMorgan Raises Tesla Price Target by 227% on Expanded Market Outlook
    June 10, 2026, 11:36 AM EDT. JPMorgan analyst Rajat Gupta sharply increased Tesla's price target from $145 to $475, a 227% rise, reflecting a fundamental shift in valuation approach. Instead of viewing Tesla solely as an automaker, Gupta values Tesla across five markets: automotive, energy storage, robotaxis, humanoid robots, and infrastructure licensing. This broader view highlights Tesla's comprehensive control of hardware, software, AI, and data, giving it a competitive edge. JPMorgan forecasts Tesla's revenue to more than double by 2030, driven by services and new tech sectors, with earnings per share nearly tripling. This aggressive outlook contrasts with bearish views focusing on Tesla's current high valuation relative to earnings.

Latest articles

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

10 June 2026
Dow drops 0.55% to 50,592 after May CPI jumps 4.2% year-on-year, matching forecasts but fueled by a 7% surge in gasoline prices and rising energy costs, as renewed U.S.-Iran tensions and sharp losses in AI and industrial stocks add to investor caution, with Super Micro Computer plunging 14.2% on $7 billion equity plans and XPO, J.B. Hunt, Old Dominion falling up to 6.2% after Amazon expands freight service.
S&P 500 Swings After Hot CPI, AI Names Under Pressure

S&P 500 Swings After Hot CPI, AI Names Under Pressure

10 June 2026
May inflation jumped 4.2%—the fastest pace since April 2023—matching forecasts but keeping the Fed on hold, as energy prices fueled the rise; S&P 500 and Nasdaq steadied after early losses, but AI-linked stocks slid, with Super Micro Computer tumbling on a $7 billion share sale plan that risks diluting investors.
Go toTop